NL275743A
(de)
*
|
1961-03-20 |
|
|
|
DD150456A5
(de)
|
1979-03-01 |
1981-09-02 |
Ciba Geigy Ag |
Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
|
DE2951400A1
(de)
|
1979-12-20 |
1981-07-02 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von n,n'-diarylaethylendiaminen oder n, n',n''-triaryldiaethylen-triaminen
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
DK196688A
(da)
*
|
1987-04-28 |
1988-10-29 |
Fujisawa Pharmaceutical Co |
Bicykliske forbindelser og fremgangsmaade til fremstilling deraf
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5676978A
(en)
|
1989-02-14 |
1997-10-14 |
Amira, Inc. |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
|
US5324731A
(en)
|
1989-02-14 |
1994-06-28 |
Amira, Inc. |
Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
|
US6040138A
(en)
|
1995-09-15 |
2000-03-21 |
Affymetrix, Inc. |
Expression monitoring by hybridization to high density oligonucleotide arrays
|
US5215882A
(en)
|
1989-11-30 |
1993-06-01 |
Ortho Diagnostic Systems, Inc. |
Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
|
EP0519596B1
(de)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5837832A
(en)
|
1993-06-25 |
1998-11-17 |
Affymetrix, Inc. |
Arrays of nucleic acid probes on biological chips
|
CA2111503A1
(en)
|
1993-12-15 |
1995-06-16 |
Mcgill University |
Apolipoprotein e polymorphism and alzheimer's disease
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
US5707807A
(en)
|
1995-03-28 |
1998-01-13 |
Research Development Corporation Of Japan |
Molecular indexing for expressed gene analysis
|
US5843974A
(en)
|
1995-06-06 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
|
US5958342A
(en)
|
1996-05-17 |
1999-09-28 |
Incyte Pharmaceuticals, Inc. |
Jet droplet device
|
US6060240A
(en)
|
1996-12-13 |
2000-05-09 |
Arcaris, Inc. |
Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
|
US5945289A
(en)
|
1996-12-20 |
1999-08-31 |
Lehrer; Steven |
Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
US5994076A
(en)
|
1997-05-21 |
1999-11-30 |
Clontech Laboratories, Inc. |
Methods of assaying differential expression
|
US20030153541A1
(en)
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
ES2276481T3
(es)
|
1997-12-12 |
2007-06-16 |
The University Of Western Ontario |
Peptido apoep1.b novedoso, composiciones y sus usos.
|
US6004755A
(en)
|
1998-04-07 |
1999-12-21 |
Incyte Pharmaceuticals, Inc. |
Quantitative microarray hybridizaton assays
|
US6048695A
(en)
|
1998-05-04 |
2000-04-11 |
Baylor College Of Medicine |
Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
|
US6087112A
(en)
|
1998-12-30 |
2000-07-11 |
Oligos Etc. Inc. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
US6906069B1
(en)
|
1999-01-08 |
2005-06-14 |
Amgen Inc. |
LXR modulators
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
US8257750B2
(en)
|
1999-04-30 |
2012-09-04 |
Kibow Biotech, Inc. |
Calcium carbonate compositions for preventing or treating hyperphosphatemia
|
MXPA01011070A
(es)
|
1999-04-30 |
2003-06-30 |
Arch Dev Corp |
Derivados de esteroides.
|
WO2001066534A2
(en)
|
2000-03-09 |
2001-09-13 |
Abbott Laboratories |
Cyclic and bicyclic diamino histamine-3 receptor antagonists
|
WO2002006451A1
(en)
|
2000-07-18 |
2002-01-24 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
WO2002013594A1
(en)
|
2000-08-17 |
2002-02-21 |
Northland Seed & Grain Corp. |
Method for minimizing contamination of crops and products derived therefrom
|
AU2001288955A1
(en)
|
2000-09-07 |
2002-03-22 |
Vanderbilt University |
Genome engineering by cell-permeable dna site-specific recombinases
|
ATE283253T1
(de)
|
2000-09-18 |
2004-12-15 |
Glaxo Group Ltd |
Substituierte aminopropoxyarylderivate als lxr agonisten
|
IL156460A0
(en)
*
|
2001-01-31 |
2004-01-04 |
Pfizer Prod Inc |
Ether derivatives useful as inhibitors of pde4 isozymes
|
CA2438221A1
(en)
|
2001-02-08 |
2002-08-15 |
The University Of Chicago |
Steroidal derivatives
|
CA2446314C
(en)
|
2001-05-03 |
2011-02-22 |
The University Of Chicago |
Liver x receptor agonists
|
US6908934B2
(en)
|
2001-06-11 |
2005-06-21 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
AU2002336433A1
(en)
|
2001-10-08 |
2003-04-22 |
Eli Lilly And Company |
Tricyclic compounds useful for modulating lxr
|
WO2003043998A1
(en)
|
2001-11-15 |
2003-05-30 |
Incyte San Diego Incorporated |
N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
|
AU2002346426A1
(en)
|
2001-11-21 |
2003-06-10 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Lxrのモジュレーター
|
EP1463726A2
(de)
|
2001-12-21 |
2004-10-06 |
Pharmacia Corporation |
Aromatische thioether als lxr-modulatoren
|
EP1465882B1
(de)
|
2001-12-21 |
2011-08-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclische modulatoren von nukleären rezeptoren
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
EP1575495A4
(de)
*
|
2002-03-27 |
2009-12-02 |
Smithkline Beecham Corp |
Verbindungen und verfahren
|
JP2005521721A
(ja)
*
|
2002-03-27 |
2005-07-21 |
スミスクライン・ビーチャム・コーポレイション |
酸およびエステル化合物ならびにその使用方法
|
WO2004043939A1
(en)
|
2002-03-27 |
2004-05-27 |
Smithkline Beecham Corporation |
Amide compounds and methods of using the same
|
US20050171084A1
(en)
|
2002-03-27 |
2005-08-04 |
Cairns William J. |
Methods of treatment with lxr modulators
|
AU2003222667A1
(en)
|
2002-04-23 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
|
AU2003223684A1
(en)
|
2002-04-23 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Lxr modulators for the treatment of cardiovascular diseases
|
AU2003228614A1
(en)
|
2002-04-23 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Lxr modulators
|
US6822120B2
(en)
|
2002-05-24 |
2004-11-23 |
Pharmacia Corporation |
Sulfone liver X-receptor modulators
|
AU2003241601A1
(en)
|
2002-05-24 |
2003-12-12 |
Pharmacia Corporation |
Anilino liver x-receptor modulators
|
EP1521584A1
(de)
|
2002-06-17 |
2005-04-13 |
Glaxo Group Limited |
Purin-derivate als leber x-rezeptor-agonisten
|
AU2003238157A1
(en)
|
2002-06-18 |
2003-12-31 |
Sankyo Company, Limited |
Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
|
WO2004009765A2
(en)
|
2002-07-19 |
2004-01-29 |
Althea Technologies, Inc. |
Strategies for gene expression analysis
|
EP1534696A4
(de)
|
2002-07-25 |
2010-04-07 |
Merck Sharp & Dohme |
Therapeutische verbindungen zur behandlung von dyslipidümieleiden
|
JP2005534710A
(ja)
|
2002-08-07 |
2005-11-17 |
ノバルティス アクチエンゲゼルシャフト |
Apoe遺伝子型を基準とした痴呆を処置するための方法
|
EP1407774A1
(de)
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-chinazolinone, die an den LXR Kernrezeptor binden
|
BR0314390A
(pt)
|
2002-09-17 |
2005-07-19 |
Pharmacia Corp |
Moduladores aromáticos dos receptores hepáticos x
|
ATE496893T1
(de)
|
2002-12-20 |
2011-02-15 |
X Ceptor Therapeutics Inc |
Isochinolinonderivate und deren verwendung als medikamente
|
WO2004072042A2
(en)
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
WO2004072041A1
(en)
|
2003-02-12 |
2004-08-26 |
Care X S.A. |
Tetrahydroquinolines as agonists of liver- x receptors
|
WO2004072046A2
(en)
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivatives and their use for modulation of lxr activity
|
WO2004078939A2
(en)
|
2003-03-03 |
2004-09-16 |
University Of Massachusetts |
REGULATION OF Mdm2 FUNCTION
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
GB0316237D0
(en)
|
2003-07-11 |
2003-08-13 |
Astrazeneca Ab |
Therapeutic agents
|
GB0316232D0
(en)
|
2003-07-11 |
2003-08-13 |
Astrazeneca Ab |
Therapeutic agents
|
US20050130919A1
(en)
|
2003-07-18 |
2005-06-16 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin RNA
|
JP2007502291A
(ja)
|
2003-08-12 |
2007-02-08 |
アムジエン・インコーポレーテツド |
アリールスルホンアミドベンジル系化合物
|
CA2535749C
(en)
|
2003-09-03 |
2011-11-01 |
Kowa Co., Ltd. |
Ppar activating compound and pharmaceutical composition containing same
|
JP2006193426A
(ja)
|
2003-09-05 |
2006-07-27 |
Sankyo Co Ltd |
置換された縮環ピリミジン−4(3h)−オン化合物
|
DK1677833T3
(da)
|
2003-10-20 |
2010-05-17 |
Nsgene As |
Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
|
US20050113419A1
(en)
|
2003-10-31 |
2005-05-26 |
Huang Shaei Y. |
Therapeutic compounds for treating dyslipidemic conditions
|
KR20070001922A
(ko)
|
2003-12-12 |
2007-01-04 |
와이어쓰 |
심장혈관질환 치료에 유용한 퀴놀린
|
FR2865736B1
(fr)
|
2004-02-02 |
2006-07-14 |
Synt Em |
Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
|
CN1918155B
(zh)
|
2004-02-11 |
2010-05-26 |
Irm责任有限公司 |
作为lxr调节剂的化合物和组合物
|
CA2553442A1
(en)
|
2004-02-11 |
2005-08-25 |
Irm Llc |
Compounds and compositions as lxr modulators
|
ATE408599T1
(de)
|
2004-03-26 |
2008-10-15 |
Hoffmann La Roche |
Tetrahydrocarbazole und derivate
|
ES2329489T3
(es)
|
2004-05-03 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
Derivados de indolilo como moduladores del receptor x del higado.
|
WO2005112620A2
(en)
|
2004-05-18 |
2005-12-01 |
Massachusetts Institute Of Technology |
A cre-lox based method for conditional rna interference
|
WO2005113499A1
(ja)
|
2004-05-20 |
2005-12-01 |
Sankyo Company, Limited |
インドール化合物
|
EP1763502A1
(de)
|
2004-06-28 |
2007-03-21 |
F.Hoffmann-La Roche Ag |
Neue hexafluorisopropanolderivate
|
TW200606133A
(en)
|
2004-06-30 |
2006-02-16 |
Sankyo Co |
Substituted benzene compounds
|
EP1764075A4
(de)
|
2004-07-02 |
2010-08-04 |
Sankyo Co |
Hemmer der gewebefaktorbildung
|
EP1765335B1
(de)
|
2004-07-07 |
2009-11-25 |
Merck & Co., Inc. |
Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
|
TW200605886A
(en)
|
2004-08-03 |
2006-02-16 |
Wyeth Corp |
Indazoles useful in treating cardiovascular diseases
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060178398A1
(en)
|
2004-09-16 |
2006-08-10 |
Adams Alan D |
Therapeutic compounds for treating dyslipidemic conditions
|
CN101031540B
(zh)
|
2004-10-01 |
2010-05-26 |
霍夫曼-拉罗奇有限公司 |
六氟异丙醇取代的醚衍生物
|
BRPI0518229A
(pt)
|
2004-10-27 |
2008-11-04 |
Daiichi Sankyo Co Ltd |
composto de benzeno tendo 2 ou mais substituintes
|
JP4644714B2
(ja)
|
2004-12-22 |
2011-03-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規なシクロヘキサン誘導体
|
EP1838685A4
(de)
|
2005-01-10 |
2010-01-27 |
Astrazeneca Ab |
Derivate von isothiazol-3-(2h)-thion-1,1-dioxiden als liver-x-rezeptormodulatoren
|
JP2008526841A
(ja)
|
2005-01-10 |
2008-07-24 |
アストラゼネカ アクチボラグ |
肝臓x受容体調節因子としてのイソチアゾール−3(2h)−オン1,1−ジオキシドのアニリン系誘導体
|
SE0500056D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 4
|
SE0500055D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 3
|
SE0500058D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 5
|
JP2006232703A
(ja)
|
2005-02-23 |
2006-09-07 |
Dai Ichi Seiyaku Co Ltd |
フェニルエーテル誘導体及びそれを用いた医薬
|
CN101166730A
(zh)
|
2005-03-01 |
2008-04-23 |
惠氏公司 |
噌啉化合物及其作为肝x受体调节剂的用途
|
CA2600159A1
(en)
|
2005-03-21 |
2006-09-28 |
Merck & Co., Inc. |
Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
|
WO2006109633A1
(ja)
|
2005-04-07 |
2006-10-19 |
Daiichi Sankyo Company, Limited |
置換インドール化合物
|
MX2008000141A
(es)
|
2005-06-27 |
2008-04-07 |
Exelixis Inc |
Moduladores de lxr basados en imidazol.
|
WO2007022563A1
(en)
|
2005-08-24 |
2007-03-01 |
Graham Scott |
Package with bitter taste aversive agent for infant deterrant
|
JP5129143B2
(ja)
|
2005-10-07 |
2013-01-23 |
エグゼリクシス, インコーポレイテッド |
Mekインヒビターおよびその使用方法
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7790745B2
(en)
|
2005-10-21 |
2010-09-07 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline LXR Modulators
|
WO2007050271A2
(en)
|
2005-10-25 |
2007-05-03 |
Wyeth |
5-lipoxygenase modulators
|
CA2627900A1
(en)
|
2005-11-14 |
2007-08-16 |
Irm Llc |
Compounds and compositions as lxr modulators
|
WO2007081335A1
(en)
|
2006-01-12 |
2007-07-19 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
EP1991586B1
(de)
|
2006-03-20 |
2011-01-12 |
Cepep III AB |
Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
|
WO2007110755A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Medical Therapies Limited |
Prophylaxis or treatment of cardiovascular inflammation
|
WO2008011071A2
(en)
|
2006-07-19 |
2008-01-24 |
The Regents Of The University Of California |
Interactions of hedgehog and liver x receptor signaling pathways
|
WO2008027988A2
(en)
|
2006-08-31 |
2008-03-06 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
|
TW200825054A
(en)
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Quinoline compounds
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
EP1925621A1
(de)
*
|
2006-11-27 |
2008-05-28 |
Novartis AG |
Kristalline Formen der Zoledronsäure
|
EP2098515B1
(de)
|
2006-11-30 |
2012-02-08 |
Kowa Company, Ltd. |
Substituierte carbinolverbindungen
|
US7998995B2
(en)
|
2006-12-08 |
2011-08-16 |
Exelixis Patent Company Llc |
LXR and FXR modulators
|
JP2008179562A
(ja)
|
2007-01-24 |
2008-08-07 |
Kowa Co |
Lxrアゴニスト
|
US8993628B2
(en)
|
2007-02-23 |
2015-03-31 |
City Of Hope |
Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
|
CN101679311A
(zh)
|
2007-05-18 |
2010-03-24 |
惠氏公司 |
喹唑啉化合物
|
JP5864100B2
(ja)
|
2007-06-29 |
2016-02-17 |
サレプタ セラピューティクス インコーポレイテッド |
組織特異的ペプチドコンジュゲートおよび方法
|
AU2008288537B2
(en)
|
2007-08-13 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Novel piperazine amide derivatives
|
TW200922582A
(en)
|
2007-08-20 |
2009-06-01 |
Organon Nv |
N-benzyl, N'-arylcarbonylpiperazine derivatives
|
US8039493B2
(en)
|
2007-09-27 |
2011-10-18 |
Hoffmann-La Roche Inc. |
Biaryl sulfonamide derivatives
|
US8440637B2
(en)
|
2007-10-04 |
2013-05-14 |
Santaris Pharma A/S |
Combination treatment for the treatment of hepatitis C virus infection
|
US7902147B2
(en)
|
2007-11-05 |
2011-03-08 |
Duke University |
Chronic lymphocytic leukemia prognosis and treatment
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
WO2009075836A2
(en)
|
2007-12-10 |
2009-06-18 |
The Brigham And Women's Hospital, Inc. |
Rap variants for drug delivery
|
EP2071509A1
(de)
|
2007-12-13 |
2009-06-17 |
Gemalto SA |
Verfahren und Vorrichtung zur Markierung eines Dokuments mit einer Kombination aus Guillochen und Wasserzeichen sowie Verfahren und Vorrichtung zur Erkennung einer solchen Kombination
|
WO2009086130A1
(en)
|
2007-12-21 |
2009-07-09 |
Wyeth |
Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
|
JP2011507901A
(ja)
|
2007-12-21 |
2011-03-10 |
ワイス・エルエルシー |
ピラゾロ[1,5−a]ピリミジン化合物
|
CA2710461A1
(en)
|
2007-12-21 |
2009-07-09 |
Wyeth Llc |
Benzimidazole compounds
|
CN101945871A
(zh)
|
2007-12-21 |
2011-01-12 |
惠氏有限责任公司 |
咪唑并[1,2-a]吡啶化合物
|
US7919509B2
(en)
|
2008-02-29 |
2011-04-05 |
Kowa Company, Ltd. |
2-oxochromene derivatives
|
JP5511080B2
(ja)
|
2008-03-31 |
2014-06-04 |
興和株式会社 |
1,3−ジヒドロイソベンゾフラン誘導体
|
WO2009133692A1
(ja)
|
2008-04-30 |
2009-11-05 |
興和株式会社 |
キノリン化合物
|
TW201006816A
(en)
|
2008-05-15 |
2010-02-16 |
Organon Nv |
Hexafluoroisopropanol derivatives
|
US8153634B2
(en)
|
2008-05-29 |
2012-04-10 |
Kowa Company, Ltd. |
Carbinol derivatives having cyclic linker
|
US20090311187A1
(en)
|
2008-05-29 |
2009-12-17 |
Bristol-Myers Squibb Company |
Methods for predicting patient response to modulation of the Co-stimulatory pathway
|
US8063088B2
(en)
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
EP2303304A4
(de)
|
2008-07-01 |
2011-09-21 |
Cognosci Inc |
Verfahren zur behandlung von krebs mit apoe-peptiden
|
TW201022230A
(en)
|
2008-08-28 |
2010-06-16 |
Organon Nv |
1-(4-ureidobenzoyl)piperazine derivatives
|
US8613367B2
(en)
|
2008-08-29 |
2013-12-24 |
Saint-Gobain Performance Plastics Corporation |
Sealing assembly and method of making such assembly
|
FR2935380B1
(fr)
|
2008-08-29 |
2010-09-10 |
Galderma Res & Dev |
Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
|
MX349463B
(es)
|
2008-09-26 |
2017-07-31 |
Univ Emory |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
MX2011003239A
(es)
|
2008-09-26 |
2011-04-28 |
Merck Sharp & Dohme |
Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
|
WO2010059627A1
(en)
|
2008-11-19 |
2010-05-27 |
Wyeth Llc |
Polar quinazolines as liver x receptors ( lxrs ) modulators
|
WO2010101888A2
(en)
|
2009-03-02 |
2010-09-10 |
Biocure Pharma, Llc |
Methods and compositions for treatment of tumor metastasis
|
TW201043613A
(en)
|
2009-04-29 |
2010-12-16 |
Kowa Co |
Carbinol derivatives having heterocyclic linker
|
AU2010254082B2
(en)
|
2009-05-28 |
2015-01-29 |
Exelixis, Inc. |
LXR modulators
|
US8829213B2
(en)
|
2009-07-29 |
2014-09-09 |
The University Of Chicago |
Liver X receptor agonists
|
KR101636958B1
(ko)
*
|
2009-09-11 |
2016-07-06 |
주식회사 대웅제약 |
우루소데옥시콜린산-합성하이드로탈사이트-유드라짓 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
|
TWI513695B
(zh)
|
2009-10-27 |
2015-12-21 |
Merck Sharp & Dohme |
(1,1,1,3,3,3-六氟-2-羥基丙-2-基)苯基衍生物
|
WO2011055391A1
(en)
|
2009-11-09 |
2011-05-12 |
Advinus Therapeutics Private Limited |
Substituted fused pyrimidine compounds, its preparation and uses thereof
|
RU2551847C2
(ru)
|
2009-12-04 |
2015-05-27 |
Тайсо Фармасьютикал Ко., Лтд. |
Производные 2-пиридона
|
US20120309730A1
(en)
|
2010-02-16 |
2012-12-06 |
The Johns Hopkins University |
Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
US9421218B2
(en)
|
2010-04-13 |
2016-08-23 |
New York University |
Compositions and methods for treatment of melanoma
|
US20130090258A1
(en)
|
2010-06-16 |
2013-04-11 |
National University Corporation Hamamatsu University School Of Medicines |
Method for detecting colorectal tumor
|
KR20130023335A
(ko)
|
2010-07-08 |
2013-03-07 |
와이어쓰 엘엘씨 |
피부 장애를 치료하는데 유용한 신규 퀴놀린 에스테르
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
US20130004481A1
(en)
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
US20120231457A1
(en)
|
2011-03-10 |
2012-09-13 |
Nikolaos Tezapsidis |
Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
|
US9629910B2
(en)
|
2011-03-22 |
2017-04-25 |
The Brigham And Women's Hospital, Inc. |
Use of Th9 cells and IL-9 for the treatment of melanoma
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
AU2013201121A1
(en)
|
2011-09-20 |
2013-04-04 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
CN103054844B
(zh)
|
2011-10-18 |
2014-04-30 |
中国科学院武汉病毒研究所 |
一种gw3965在制备治疗或预防丙型肝炎药物中的应用
|
EP2768841B1
(de)
|
2011-10-18 |
2017-09-27 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Säureadditionssalze von 5alpha-hydroxy-6beta-[2-(1h-imidazol-4-yl)ethylamino]cholestan-3beta-ol
|
IN2014MN00976A
(de)
|
2011-11-24 |
2015-04-24 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
EP3441390A1
(de)
|
2012-03-02 |
2019-02-13 |
Ralexar Therapeutics, Inc. |
Leber-x-rezeptor (lxr)-modulatoren zur behandlung von hautkrankheiten, -störungen und -leiden
|
WO2013138565A1
(en)
|
2012-03-16 |
2013-09-19 |
Vitae Pharmaceuticals, Inc. |
Liver x receptor modulators
|
US9073931B2
(en)
|
2012-03-16 |
2015-07-07 |
Vitae Pharmaceuticals, Inc. |
Liver X receptor modulators
|
CA2882292C
(en)
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
EP2968275B1
(de)
|
2013-03-15 |
2017-11-29 |
Bristol-Myers Squibb Company |
Lxr-modulatoren
|
JP6066860B2
(ja)
|
2013-08-05 |
2017-01-25 |
株式会社クボタ |
草刈機
|
WO2015065505A1
(en)
|
2013-10-29 |
2015-05-07 |
Duke University |
Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
|
CA2939120A1
(en)
*
|
2014-01-10 |
2015-07-16 |
Rgenix, Inc. |
Lxr agonists and uses thereof
|
CA2916564C
(en)
|
2014-02-07 |
2023-02-28 |
Global Blood Therapeutics, Inc. |
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
CN107072984B
(zh)
|
2014-07-15 |
2021-10-01 |
约翰·霍普金斯大学 |
源自骨髓的抑制细胞的抑制和免疫检查点阻断
|
WO2016100619A2
(en)
|
2014-12-17 |
2016-06-23 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
WO2016149299A1
(en)
|
2015-03-16 |
2016-09-22 |
Epinova Therapeutics Corp. |
Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
|
US20170056352A1
(en)
|
2015-08-25 |
2017-03-02 |
Rgenix, Inc. |
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
SG10201912150TA
(en)
|
2015-10-06 |
2020-02-27 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
CA3010883A1
(en)
|
2016-01-11 |
2017-07-20 |
The Rockefeller University |
Methods for the treatment of myeloid derived suppressor cells related disorders
|
WO2017161188A1
(en)
|
2016-03-16 |
2017-09-21 |
The Regents Of The University Of California |
Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
|
WO2017181163A2
(en)
|
2016-04-16 |
2017-10-19 |
Oncocyte Corporation |
Methods and compositions for detection and diagnosis of breast cancer
|
EP3778643A1
(de)
|
2016-09-14 |
2021-02-17 |
AbbVie Biotherapeutics Inc. |
Pharmazeutische anwendungen von anti-pd-1-antikörper (cd279)
|
WO2018160178A1
(en)
|
2017-03-01 |
2018-09-07 |
Rgenix, Inc. |
Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
|
US11629118B2
(en)
*
|
2017-03-03 |
2023-04-18 |
Inspirna, Inc. |
Formulations with improved stability
|
US11214536B2
(en)
|
2017-11-21 |
2022-01-04 |
Inspirna, Inc. |
Polymorphs and uses thereof
|
CN109251974A
(zh)
|
2018-02-14 |
2019-01-22 |
重庆京因生物科技有限责任公司 |
基于poct模式的apoe2和apoe4基因型快速检测试剂盒
|
EP3931349A4
(de)
|
2019-02-28 |
2023-02-08 |
The Rockefeller University |
Apoe-genotyping in der krebsprognose und -therapie
|
WO2020205644A1
(en)
|
2019-03-29 |
2020-10-08 |
Biontech Us Inc. |
Cancer biomarkers for durable clinical benefit
|
MX2022007164A
(es)
|
2019-12-13 |
2022-09-12 |
Inspirna Inc |
Sales metálicas y usos de estas.
|